Aptus Pharma Limited Reports Robust 47% Revenue Growth in H1
Aptus Pharma Limited announced robust financial results for H1 FY24. Total revenue increased by 47.38% to Rs. 1,437.75 lakhs, EBITDA grew by 36.12% to Rs. 294.55 lakhs, and PAT rose by 33.81% to Rs. 174.69 lakhs compared to the previous year. The company experienced slight margin compression with EBITDA margin at 20.49% and PAT margin at 12.15%. Growth was attributed to product portfolio expansion, strengthened marketing network, and improved operational efficiency. The company plans to continue investing in new products, digital initiatives, and distribution expansion.
*this image is generated using AI for illustrative purposes only.
Aptus Pharma Limited (BSE: 544529), a fast-growing pharmaceutical company focused on sales and marketing of high-quality medicines, has announced strong financial results for the first half ended September 30. The company has demonstrated solid growth momentum and operational excellence across key financial parameters.
Key Financial Highlights
| Particulars (Rs. in Lakhs) | H1 Current | H1 Previous | YoY Growth |
|---|---|---|---|
| Total Revenue | 1,437.75 | 975.57 | 47.38% |
| EBITDA | 294.55 | 216.39 | 36.12% |
| EBITDA Margin | 20.49% | 22.18% | -169 bps |
| PAT | 174.69 | 130.55 | 33.81% |
| PAT Margin | 12.15% | 13.38% | -123 bps |
Performance Overview
Aptus Pharma Limited (APL) has delivered a strong performance for the first half, continuing its growth momentum across key financial and operational parameters. The company's revenue grew by 47.38% year-over-year, while EBITDA increased by 36.12%. Profit After Tax (PAT) recorded a significant growth of 33.81% compared to the corresponding period of the previous year.
This performance reflects the success of APL's strategic initiatives, including:
- Expansion of product portfolio
- Strengthening of marketing network
- Driving higher operational efficiency
Despite a competitive environment, the company achieved healthy growth in both acute and chronic therapy segments. This growth was supported by new product launches and enhanced field force productivity.
Margin Performance
While the company saw strong top-line and bottom-line growth, there was a slight compression in margins:
- EBITDA margin decreased by 169 basis points to 20.49% from 22.18% in the previous period
- PAT margin declined by 123 basis points to 12.15% from 13.38% in the same period last year
The company attributes the maintained profitability to its focus on disciplined cost management and efficient resource utilization.
Management Commentary
Mr. Tejash Hathi, Managing Director of Aptus Pharma Limited, commented on the results: "Our strong performance in the first half is a reflection of the collective effort, passion, and dedication of our employees across every function of the organisation. We firmly believe that our people are the biggest reason behind our success. Their commitment to excellence, agility in execution, and unwavering focus on serving patients have been the driving forces of APL's growth story."
Future Outlook
Looking ahead, APL expressed confidence in maintaining its growth trajectory in the second half. The company plans to:
- Continue investing in new product introductions
- Implement digital engagement initiatives
- Expand its distribution reach
These efforts aim to drive long-term value for all stakeholders.
Other Key Points
- The company's Board of Directors approved the unaudited financial results in a meeting held on November 10.
- The trading window for designated persons will open from November 13, in accordance with SEBI regulations.
- As of September 30, the IPO proceeds of Rs. 1,302 lakhs remain unutilized, indicating potential for future investments or expansions.
Aptus Pharma Limited continues to prioritize quality, compliance, and ethical marketing practices. The company remains committed to ensuring greater accessibility of affordable and effective medicines to patients across India.
19
